HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4663人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308609, encodeId=df51130860995, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, objectType=article, longId=220088, objectId=133b22008853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133b22008853, replyNumber=0, likeNumber=92, createdTime=2021-11-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133b22008853, moduleTitle=Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133b22008853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308608, encodeId=1b5613086086e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, objectType=article, longId=219118, objectId=d4b221911890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4b221911890, replyNumber=0, likeNumber=91, createdTime=2021-10-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4b221911890, moduleTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4b221911890)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308607, encodeId=8abf130860e97, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, objectType=article, longId=219072, objectId=03b82190e28e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b82190e28e, replyNumber=0, likeNumber=82, createdTime=2021-10-24, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b82190e28e, moduleTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b82190e28e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308606, encodeId=8228130860686, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=CSCO大会速递 | 一项吡咯替尼联合长春瑞滨治疗HER2阳性MBC多中心、回顾性研究, objectType=article, longId=217928, objectId=1fd121e928df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fd121e928df, replyNumber=0, likeNumber=0, createdTime=2021-10-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fd121e928df, moduleTitle=CSCO大会速递 | 一项吡咯替尼联合长春瑞滨治疗HER2阳性MBC多中心、回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fd121e928df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308605, encodeId=d0191308605ca, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, objectType=article, longId=217767, objectId=989c21e7670d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989c21e7670d, replyNumber=0, likeNumber=94, createdTime=2021-09-29, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989c21e7670d, moduleTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989c21e7670d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308604, encodeId=00d9130860442, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, objectType=article, longId=217554, objectId=e59521e554a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59521e554a3, replyNumber=0, likeNumber=98, createdTime=2021-09-25, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59521e554a3, moduleTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59521e554a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308603, encodeId=02c31308603db, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%, objectType=article, longId=215485, objectId=ed4b21548574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4b21548574, replyNumber=0, likeNumber=68, createdTime=2021-08-11, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4b21548574, moduleTitle=新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed4b21548574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308602, encodeId=b51c13086021b, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, objectType=article, longId=215483, objectId=b69b21548371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b69b21548371, replyNumber=0, likeNumber=90, createdTime=2021-08-11, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b69b21548371, moduleTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b69b21548371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308601, encodeId=a1061308601f6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, objectType=article, longId=215273, objectId=4e602152e3e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e602152e3e8, replyNumber=0, likeNumber=117, createdTime=2021-08-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e602152e3e8, moduleTitle=Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e602152e3e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308600, encodeId=e8711308600c6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=82, createdTime=2021-07-24, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308599, encodeId=efb91308599ad, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, objectType=article, longId=214034, objectId=f1b7214034fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1b7214034fe, replyNumber=0, likeNumber=70, createdTime=2021-07-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1b7214034fe, moduleTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1b7214034fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308598, encodeId=732d130859854, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性早期乳腺癌的标准治疗选择是什么？, objectType=article, longId=213800, objectId=532c21380055, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=532c21380055, replyNumber=0, likeNumber=71, createdTime=2021-07-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=532c21380055, moduleTitle=HER2阳性早期乳腺癌的标准治疗选择是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=532c21380055)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308597, encodeId=f478130859e1f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性, objectType=article, longId=212437, objectId=bdbb21243e30, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdbb21243e30, replyNumber=0, likeNumber=70, createdTime=2021-06-09, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdbb21243e30, moduleTitle=Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdbb21243e30)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308596, encodeId=440c130859643, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）, objectType=article, longId=212244, objectId=5e4321224412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e4321224412, replyNumber=0, likeNumber=86, createdTime=2021-06-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e4321224412, moduleTitle=ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e4321224412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308595, encodeId=63d81308595f9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Gastric Cancer：Trastuzumab deruxtecan （T-DXd或DS-8201）在HER2阳性胃癌患者的疗效以及安全性管理, objectType=article, longId=211486, objectId=7d0921148685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0921148685, replyNumber=0, likeNumber=33, createdTime=2021-05-19, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0921148685, moduleTitle=Gastric Cancer：Trastuzumab deruxtecan （T-DXd或DS-8201）在HER2阳性胃癌患者的疗效以及安全性管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0921148685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308594, encodeId=372b13085941e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, objectType=article, longId=211004, objectId=c2ae2110047c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ae2110047c, replyNumber=0, likeNumber=84, createdTime=2021-05-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ae2110047c, moduleTitle=JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ae2110047c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308593, encodeId=1f921308593b4, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, objectType=article, longId=210899, objectId=70f82108996e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70f82108996e, replyNumber=0, likeNumber=62, createdTime=2021-05-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70f82108996e, moduleTitle=Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70f82108996e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308592, encodeId=26a713085921d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响, objectType=article, longId=209810, objectId=5d9620981043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9620981043, replyNumber=0, likeNumber=103, createdTime=2021-04-12, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9620981043, moduleTitle=JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9620981043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308591, encodeId=1d2b130859179, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物, objectType=article, longId=207595, objectId=f31120e5958c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31120e5958c, replyNumber=0, likeNumber=64, createdTime=2021-02-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31120e5958c, moduleTitle=Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31120e5958c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308590, encodeId=540c130859083, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, objectType=article, longId=207278, objectId=c7b720e278ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7b720e278ca, replyNumber=0, likeNumber=69, createdTime=2021-02-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7b720e278ca, moduleTitle=欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7b720e278ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Eur J Cancer：HER2阳性早期可手术乳腺癌患者中，术前曲妥珠单抗联合依维莫司的疗效和预测标志物探索

2021-11-12

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效

2021-10-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究

2021-10-24

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

CSCO大会速递 | 一项吡咯替尼联合长春瑞滨治疗HER2阳性MBC多中心、回顾性研究

2021-10-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性

2021-09-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%

2021-09-25

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

新一代ADC类药物ARX788对HER2阳性乳腺癌ORR达74%

2021-08-11

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险

2021-08-11

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：帕妥珠单抗+曲妥珠单抗治疗HER2阳性转移性胆道癌的疗效和安全性

2021-08-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2021-07-24

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析

2021-07-12

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性早期乳腺癌的标准治疗选择是什么？

2021-07-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Nat Commun：FOXO3a-miRNA负反馈抑制作用影响HER2阳性乳腺癌的赫赛汀耐药性

2021-06-09

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）

2021-06-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Gastric Cancer：Trastuzumab deruxtecan （T-DXd或DS-8201）在HER2阳性胃癌患者的疗效以及安全性管理

2021-05-19

智智灵药 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：帕妥珠单抗联合高剂量曲妥珠单抗有望改善伴有脑转移的HER2阳性乳腺癌患者的预后

2021-05-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：曲妥珠单抗德鲁替康用于HER2阳性转移性结直肠癌的疗效和安全性

2021-05-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：辅助化疗对HER2阳性乳腺癌老年患者生活质量的影响

2021-04-12

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet子刊：国内创新药哌罗替尼有望成为HER2阳性乳腺癌替代治疗药物

2021-02-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

欧盟批准Tukysa，用于治疗HER2阳性的局部晚期或转移性乳腺癌

2021-02-20

科室
- - 订阅+
  - 更多科室
工具
服务